[{"Assets_0_Q3_USD":46700000.0,"CommonStockSharesOutstanding_0_Q3_shares":38649237.0,"EarningsPerShareBasic_1_Q3_USD":-0.11,"EarningsPerShareBasic_3_Q3_USD":-0.61,"EarningsPerShareDiluted_1_Q3_USD":-0.11,"EarningsPerShareDiluted_3_Q3_USD":-0.61,"NetIncomeLoss_1_Q3_USD":-4400000.0,"NetIncomeLoss_3_Q3_USD":-23500000.0,"StockholdersEquity_0_Q3_USD":24200000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":38647487.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":38642786.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":38647487.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":38642786.0,"Ticker":"VXRT","CIK":"72444","name":"AVIRAGEN THERAPEUTICS, INC.","OfficialName":"Vaxart Inc Common Stock","form":"10-Q","period":"20170331","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"564888665.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20170508"}]